Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease

Chopra, Yogi; Acevedo, Karol; Muise, Aleixo; Frost, Karen; Schechter, Tal; Krueger, Joerg; Ali, Muhammad; Chiang, Kuang-Yueh; Kim, Vy Hong-Diep; Grunebaum, Eyal; Wall, Donna

doi:10.1016/j.jtct.2024.03.006

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2024.03.006

|View full text |Cite

Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease

Yogi Chopra,

Karol Acevedo,

Aleixo Muise

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations

Williams

2024

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review Allogeneic hematopoietic cell transplantation (HCT) is a curative option for many for inborn errors of immunity (IEI). This review highlights recent progress in the field of HCT for IEI. Recent findings Alternative donor transplantation continues to expand donor options for patients with IEI. Reduced intensity and reduced toxicity conditioning approaches are being investigated and optimized. Immunomodulatory bridging therapies are yielding impressive progress in outcomes for primary immune regulatory disorders (PIRD) but require further study in prospective trials. Single-institution, multicenter and consortium studies have improved our understanding of factors that affect overall outcomes in IEI and outcomes in Wiskott–Aldrich syndrome (WAS), chronic granulomatous disease (CGD) and PIRD in particular. Data show that second HCT offers a viable chance of cure to some IEI patients. Late effects in IEI HCT survivors are being better characterized. Preclinical studies of chemo(radiation)-free HCT strategies hold promise for decreasing HCT toxicity. Summary Improvements in our understanding of HCT donor choice, conditioning regimen, immunomodulatory bridging therapies, diagnostic and post-HCT surveillance testing and late effects continue to yield advancements in the field of HCT for IEI.

show abstract

Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations

Williams

2024

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease

Cited by 1 publication

References 12 publications

Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations

Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations

Contact Info

Product

Resources

About